TQC3721 Suspension for Inhalation
Phase 3
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.TQC3721 Suspension for Inhalation is one of 40 therapeutic programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
39
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
119 competitors in Chronic Obstructive Pulmonary Disease
#DrugCompanyPhaseTrials
1Lunsekimig
SanofiPhase 3
CM310
KKeymed Biosciences Co.Ltd
Phase 3
Sildenafil ODT
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Tozorakimab
AstraZenecaPhase 3
Astegolimab
RochePhase 3
CM512
KKeymed Biosciences Co.Ltd
Phase 2
Avinza
HHikma Pharmaceuticals LLC
Phase 2
TQC3721 Suspension for Inhalation
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Phase 3
RLS-0071
RReAlta Life Sciences, Inc.
Phase 2
Calciferol
Jazz PharmaceuticalsPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 3[1]